Provided are novel crystalline forms of Elacestrant (Referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline form, and uses of the crystalline form for preparing estrogen receptor depressant drugs and drugs for treating breast cancer with ER+, HER2−, ESR1 mutations.
Provided are novel crystalline forms of Elacestrant (Referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline form, and uses of the crystalline form for preparing estrogen receptor depressant drugs and drugs for treating breast cancer with ER+, HER2−, ESR1 mutations.
C07C 217/84 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes amino et des groupes hydroxy éthérifiés liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné ayant des groupes amino et des groupes hydroxy éthérifiés liés à des atomes de carbone de cycles aromatiques à six chaînons non condensés du même cycle aromatique à six chaînons non condensé l'atome d'oxygène d'au moins un des groupes hydroxy éthérifiés étant lié de plus à un atome de carbone acyclique
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
2.
CRYSTAL FORM OF ZIPALERTINIB, AND PREPARATION METHOD THEREFOR AND USE THEREOF
The present invention relates to a new crystal form of Zipalertinib, a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of an EGFR inhibitor drug and a drug for treating non-small cell lung cancer with an EGFR exon 20 insertion mutation.
The present invention relates to a novel crystal form of iclepertin, a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in the preparation of a GlyT1 inhibitor drug and a drug for a cognitive disorder related to schizophrenia.
C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
Provided are a crystal form of zasocitinib and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in preparation of a TYK2 inhibitor drug and a drug for treating psoriasis, psoriatic arthritis, inflammatory bowel diseases, and other autoimmune diseases.
A novel crystalline form of Tavapadon (hereinafter referred to as “Compound I”) and its preparation method, pharmaceutical compositions containing this crystalline form, and its use in the preparation of dopamine D1/D5 receptor agonist drugs and in the treatment of Parkinson's disease. The crystalline form of Compound I provided by the present disclosure has one or more improved properties compared to prior arts, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.
A novel crystalline form of Tavapadon (hereinafter referred to as “Compound I”) and its preparation method, pharmaceutical compositions containing this crystalline form, and its use in the preparation of dopamine D1/D5 receptor agonist drugs and in the treatment of Parkinson's disease. The crystalline form of Compound I provided by the present disclosure has one or more improved properties compared to prior arts, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
6.
CRYSTAL FORM OF BEZUCLASTINIB, PREPARATION METHOD THEREFOR AND USE THEREOF
The present invention relates to a crystal form of Bezuclastinib and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in preparation of drugs for inhibiting KIT D816V mutations and drugs for treating gastrointestinal stromal tumor and progressive systemic mastocytosis.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/4162 - 1,2-Diazoles condensés avec des systèmes hétérocycliques
The present invention relates to a new crystal form of Resmetirom and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in preparation of a THR-β selective agonist pharmaceutical formulation and a pharmaceutical formulation for treating MASH and HeFH.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61P 5/16 - Médicaments pour le traitement des troubles du système endocrinien des hormones thyroïdiennes, p. ex. T3, T4 pour réduire, bloquer ou contrarier l'activité des hormones thyroïdiennes
8.
CRYSTAL FORM OF BAXDROSTAT, AND PREPARATION METHOD THEREFOR AND USE THEREOF
A new crystal form of Baxdrostat, and a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of an aldosterone synthase inhibitor drug and a drug for treating hypertension, primary aldosteronism and chronic kidney disease.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles
Provided are novel crystalline forms of Nirogacestat (Referred to as “Compound I”) dihydrobromide and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing γ-secretase inhibitor drugs and drugs for treating desmoid tumors. Compared with prior arts, the provided crystalline forms of Compound I dihydrobromide have one or more improved properties, which solve the problems of the prior art and are of great value to the optimization and development of the drugs.
Provided are novel crystalline forms of Nirogacestat (Referred to as “Compound I”) dihydrobromide and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing γ-secretase inhibitor drugs and drugs for treating desmoid tumors. Compared with prior arts, the provided crystalline forms of Compound I dihydrobromide have one or more improved properties, which solve the problems of the prior art and are of great value to the optimization and development of the drugs.
A novel crystal form of Nirogacestat dihydrobromate, a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a gamma secretase inhibitor drug and a drug for treating desmoid.
The present invention relates to a co-crystal of Aficamten and tartaric acid, a preparation method therefor, a pharmaceutical composition containing the co-crystal, and the use of the co-crystal in the preparation of a cardiac myosin inhibitor drug and a drug for treating hypertrophic cardiomyopathy.
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
The present invention relates to a novel crystal form of pirtobrutinib, a preparation method therefor, a pharmaceutical composition containing said crystal form, and use of the crystal form in the preparation of an oral non-covalent BTK inhibitor drug and a drug for treating cellular lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma.
The present invention provides novel crystalline forms of Xevinapant and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing IAPs drugs and drugs for treating LA SCCHN.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p. ex. kétorolac, physostigmine
The present invention relates to a new crystal form of Enpatoran (hereinafter referred to as "compound I"), and a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a TLR7/8 inhibitor drug and a drug for treating cutaneous lupus erythematosus and systemic lupus erythematosus.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
15.
CRYSTAL FORM OF APROCITENTAN, PREPARATION METHOD THEREFOR AND USE THEREOF
The present invention relates to a novel crystal form of aprocitentan (referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of dual endothelin receptor antagonist drugs and drugs for treating resistant hypertension.
The present invention relates to a crystal form of darovasertib (hereinafter referred to as "compound I"), a method for preparing same, a pharmaceutical composition comprising the crystal form, and the use of the crystal form in treating uveal melanoma.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
The present invention relates to a co-crystal of elacestrant (hereinafter referred to as "compound (I)") dihydrochloride and a preparation method therefor, a pharmaceutical composition comprising the co-crystal, and a use of the co-crystal in the preparation of an estrogen receptor degradation agent drug and a drug for treating estrogen receptor positive breast cancers or human epidermal growth factor receptor 2 negative breast cancers.
C07C 217/84 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes amino et des groupes hydroxy éthérifiés liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné ayant des groupes amino et des groupes hydroxy éthérifiés liés à des atomes de carbone de cycles aromatiques à six chaînons non condensés du même cycle aromatique à six chaînons non condensé l'atome d'oxygène d'au moins un des groupes hydroxy éthérifiés étant lié de plus à un atome de carbone acyclique
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
The present invention relates to a crystal form of Emraclidine (hereinafter referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and use of the crystal form in the preparation of an M4 receptor modulator medicament and a medicament for treating schizophrenia.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
19.
CRYSTAL FORM OF XEVINAPANT, METHOD FOR PREPARING SAME AND USE THEREOF
The present invention relates to a crystal form of compound Xevinapant and a method for preparing same, a pharmaceutical composition containing same, and use thereof in the preparation of an inhibitor drug for inhibitors of apoptosis protein and a drug for treating head and neck squamous cell carcinoma.
C07D 487/00 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
The present invention relates to a new crystal form of Resmetirom (referred to as “Compound I”) and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and a use of the crystal form in preparing a THR-β selective agonist drug and a drug for treating NASH and HeFH. Compared with the prior art, the provided crystal form of the compound I has one or more improved properties, solves problems existing in the prior art, and has a great value for the optimization and development of drugs containing the compound I.
The present invention relates to a new crystal form of Resmetirom (referred to as “Compound I”) and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and a use of the crystal form in preparing a THR-β selective agonist drug and a drug for treating NASH and HeFH. Compared with the prior art, the provided crystal form of the compound I has one or more improved properties, solves problems existing in the prior art, and has a great value for the optimization and development of drugs containing the compound I.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
21.
CRYSTAL FORM OF ELACESTRANT DIHYDROCHLORIDE, PREPARATION METHOD THEREFOR, AND USE THEREOF
The present invention relates to a novel crystal form of elacestrant (hereinafter referred to as "compound I") dihydrochloride, a preparation method therefor, a pharmaceutical composition containing the crystal form, and uses of the crystal form in the preparation of an estrogen receptor degrader drug and a drug for treating estrogen receptor-positive breast cancer, human epidermal growth factor receptor 2-negative breast cancer, or ESR1-mutated breast cancer.
C07C 217/84 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes amino et des groupes hydroxy éthérifiés liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné ayant des groupes amino et des groupes hydroxy éthérifiés liés à des atomes de carbone de cycles aromatiques à six chaînons non condensés du même cycle aromatique à six chaînons non condensé l'atome d'oxygène d'au moins un des groupes hydroxy éthérifiés étant lié de plus à un atome de carbone acyclique
The present invention relates to a novel crystal form of blarcamesine (hereinafter referred to as "compound I") hydrochloride, a method for preparing same, a pharmaceutical composition comprising the crystal form, and use of the crystal form in preparing a Sigma -1 receptor agonist and a medicament for treating Rett syndrome, Alzheimer's disease, and Parkinson's disease dementia.
C07D 307/14 - Radicaux substitués par des atomes d'azote ne faisant pas partie d'un radical nitro
A61K 31/341 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide non condensés avec un autre cycle, p. ex. ranitidine, furosémide, bufétolol, muscarine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
23.
CRYSTAL FORM OF NIROGACESTAT DIHYDROBROMIDE, AND PREPARATION METHOD THEREFOR AND USE THEREOF
The present invention relates to a novel crystal form of nirogacestat (hereinafter referred to as "compound I") dihydrobromide, and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in preparation for a γ secretase inhibitor medication and a medication for treating a desmoid tumor. Compared with the prior art, the crystal form of the compound I dihydrobromide provided by the present invention has one or more improved properties, solves the problems in the prior art, and has important values for optimization and development of medications in the future.
A new crystal form of tavapadon (hereinafter referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a dopamine D1/D5 receptor agonist drug and a drug for treating Parkinson's disease. The crystal form of the compound I has one or more improved properties than the prior art, solves the problems in the prior art, and is of great value to the optimization and development of the drug in the future.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
25.
CRYSTAL FORM OF LANIFIBRANOR, PREPARATION METHOD THEREFOR, AND USE THEREOF
Provided are a crystal form of Lanifibranor (hereinafter referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in the preparation of pan-PPAR agonist drugs and drugs for the treatment of nonalcoholic steatohepatitis. The provided novel crystal form of compound I has one or more improved properties with respect to the prior art, resolves an existing problem in the prior art, and has great value for the optimisation and development of drugs containing compound I.
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/428 - Thiazoles condensés avec des carbocycles
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
26.
DEUCRAVACITINIB CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF
Disclosed are a crystal form of a compound (I) and a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a TYK2 inhibitor drug and a drug for treating psoriasis, systemic lupus erythematosus, and Crohn’s disease. The crystal form of compound I has one or more improved properties compared with the prior art and is of great value to the future optimization and development of the drug.
Disclosed are a crystal form of a compound (I) and a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a TYK2 inhibitor drug and a drug for treating psoriasis, systemic lupus erythematosus, and Crohn’s disease. The crystal form of compound I has one or more improved properties compared with the prior art and is of great value to the future optimization and development of the drug.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
27.
BMS-986165 CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF
A crystal form of a compound I and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in the preparation of a TYK2 inhibitor drug and a drug for treating psoriasis, systemic lupus erythematosus, and Crohn's disease. The crystallization of the compound I has one or more improved properties compared to the existing technology, and has an important value to the future optimization and development of the drug.
A crystal form of a compound I and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in the preparation of a TYK2 inhibitor drug and a drug for treating psoriasis, systemic lupus erythematosus, and Crohn's disease. The crystallization of the compound I has one or more improved properties compared to the existing technology, and has an important value to the future optimization and development of the drug.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
28.
CRYSTAL FORM OF TOLEBRUTINIB, PREPARATION METHOD THEREFOR AND USE THEREOF
The present invention relates to a new crystal form of tolebrutinib (hereinafter referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of same in the preparation of a BTK inhibitor drug and a drug for treating multiple sclerosis. The crystal form of tolebrutinib provided has one or more improved properties compared with the prior art, and is of great value to the optimization and development of drugs in the future.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
Novel crystalline forms of Resmetirom (Referred to as “Compound I”), and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing THR-β selective agonist drugs and drugs for treating NASH and HeFH. Compared with prior arts, the provided crystalline forms of Compound I have one or more improved properties, which is of great value to the optimization and development of the drugs containing Compound I.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
30.
Co-crystal of Compound I Dihydrochloride and Preparation Method and Use Thereof
Provided are co-crystals of Compound I dihydrochloride and preparation methods thereof, pharmaceutical compositions containing the co-crystals, and uses of the co-crystals for preparing cardiac muscle myosin agonist drugs and drugs for treating heart failure. Compared with prior arts, the provided co-crystals of Compound I dihydrochloride have one or more improved properties, which solve the problems of prior arts and are of great value to the optimization and development of the drugs.
C07D 213/75 - Radicaux amino ou imino, acylés par un acide carboxylique, par l'acide carbonique ou par leurs analogues du soufre ou de l'azote, p. ex. des carbamates
31.
CRYSTALLINE FORM OF VALBENAZINE DITOSYLATE, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF
A crystalline form of valbenazine ditosylate, processes for preparation thereof, a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing vesicular monoamine transporter 2 inhibitor drugs, and use of the crystalline form for preparing drugs treating tardive dyskinesia.
A crystalline form of valbenazine ditosylate, processes for preparation thereof, a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing vesicular monoamine transporter 2 inhibitor drugs, and use of the crystalline form for preparing drugs treating tardive dyskinesia.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
32.
CRYSTAL FORM OF BEUMOSUL MESYLATE, PREPARATION METHOD FOR CRYSTAL FORM, AND USE THEREOF
The present invention relates to a crystal form of Belumosudil (hereinafter referred to as compound I) mesylate and a preparation method for the crystal form, a pharmaceutical composition comprising the crystal form, and a use of the crystal form in the preparation of ROCK2 inhibitor drugs and drugs for treating chronic graft versus host disease, systemic sclerosis, and idiopathic pulmonary fibrosis. Compared with the prior art, the crystal form of Belumosudil mesylate provided by the present invention has one or more improved properties, and has important value for the optimization and development of the drugs in the future.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
33.
CRYSTAL FORM OF HYPOXIA-INDUCIBLE FACTOR-PROLYL HYDROXYLASE INHIBITOR
A novel crystalline form of Compound I and preparation methods thereof, pharmaceutical compositions containing the crystalline form, and uses of the crystalline form for preparing hypoxia inducible factor prolyl hydroxylase inhibitor drugs and drugs for treating conditions mediated by hypoxia inducible factors. Compared with prior arts, the crystalline form of Compound I have one or more improved properties, which is of great value to the optimization and development of the drugs.
A novel crystalline form of Compound I and preparation methods thereof, pharmaceutical compositions containing the crystalline form, and uses of the crystalline form for preparing hypoxia inducible factor prolyl hydroxylase inhibitor drugs and drugs for treating conditions mediated by hypoxia inducible factors. Compared with prior arts, the crystalline form of Compound I have one or more improved properties, which is of great value to the optimization and development of the drugs.
Provided are a novel crystal form of Odevixibat (referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing said crystal form, and a use of said crystal form in the preparation of a IBAT inhibitor drug and a drug for treating progressive familial intrahepatic cholestasis, biliary atresia, and Alagille syndrome. The crystal form of compound I provided by the present invention has one or more improved properties with respect to the prior art, resolves an existing problem the prior art, and has great value for the optimization and development of medicament containing compound I in the future.
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. clothiapine, diltiazem
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
35.
Crystal form of upadacitinib, preparation method therefor, and use thereof
Crystalline forms of upadacitinib and processes for preparation thereof are disclosed. The present disclosure also relates to pharmaceutical compositions containing the upadacitinib crystalline forms, use of the upadacitinib crystalline forms for preparing JAK1 inhibitor drugs, and use of the upadacitinib crystalline forms for preparing drugs treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis and psoriatic arthritis. The crystalline forms of upadacitinib provided by the present disclosure have one or more improved properties compared with prior arts and have significant values for future drug optimization and development.
Provided are a new crystal form of Lanifibranor (referred to as "compound I") and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in preparation of a pan-PPAR agonist drug and a drug for treating non-alcoholic steatohepatitis. Compared with the prior art, the provided new crystal form of the compound I has one or more improved properties, solves the problems existing in the prior art, and is of great value to the optimization and development of the drug containing the compound I.
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 209/12 - Radicaux substitués par des atomes d'oxygène
A61K 31/428 - Thiazoles condensés avec des carbocycles
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
37.
CRYSTAL FORM OF TOLEBRUTINIB, PREPARATION METHOD THEREFOR AND USE THEREOF
Provided are a crystal form of Tolebrutinib (hereinafter referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a BTK inhibitor drug and a drug for treating multiple sclerosis. The crystal form of Tolebrutinib has one or more improved properties compared with the prior art, and is of great value to the optimization and development of the drug in the future.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
Provided are a new crystal form of Gefapixant (referred to as "compound I") citrate and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in the preparation of P2X3 receptor antagonist drugs and drugs for treating chronic cough. The provided new crystal form of the compound I citrate has one or more improved properties compared to the prior art, solves the problems existing in the prior art, and has important value on the optimization and development of drugs containing the compound I citrate.
C07D 239/28 - Composés hétérocycliques contenant des cycles diazine-1, 3 ou diazine-1, 3 hydrogéné non condensés avec d'autres cycles comportant au moins trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, liés directement aux atomes de carbone du cycle
A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
Provided are a new crystal form of Avacopan (referred to as "compound I") and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in the preparation of a C5aR inhibitor drug and a drug for treating antineutrophil cytoplasmic antibody associated vasculitis. Compared with the prior art, the provided new crystal form of the compound I has one or more improved properties, solves problems existing in the prior art, and has a great value for the optimization and development of drugs containing the compound I.
C07D 211/60 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
40.
CRYSTAL FORM OF RESMETIROM, PREPARATION METHOD THEREFOR, AND USE THEREOF
The present invention relates to a new crystal form of Resmetirom (referred to as "compound I") and a preparation method therefor, a pharmaceutical composition comprising the crystal from, and a use of the crystal form in preparing a THR-β selective agonist drug and a drug for treating NASH and HeFH. Compared with the prior art, the provided crystal form of the compound I has one or more improved properties, solves problems existing in the prior art, and has a great value for the optimization and development of drugs containing the compound I.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/02 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 5/14 - Médicaments pour le traitement des troubles du système endocrinien des hormones thyroïdiennes, p. ex. T3, T4
41.
CRYSTAL FORM OF RISDIPLAM, PREPARATION METHOD THEREFOR, AND USE THEREOF
Provided are a new crystal form of Risdiplam (referred to as "compound I") and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in preparation of a drug for treating spinal muscular atrophy. Compared with the prior art, the provided new crystal form of the compound I has one or more improved properties, solves the problems existing in the prior art, and is of great value to the optimization and development of said drug in the future.
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
42.
CRYSTALLINE FORM CSV OF BMS-986165 HYDROCHLORIDE, PREPARATION METHOD THEREFOR, AND USES THEREOF
Provided are a crystalline form of a compound I hydrochloride, a preparation method therefor, a pharmaceutical composition containing the crystalline form, and uses of the crystalline form in the preparation of a TYK2 inhibitor pharmaceutical and a pharmaceutical for treating psoriasis, systemic lupus erythematosus, and Crohn's disease. Compared to the prior art, the crystalline form of the compound I hydrochloride has one or more improved properties, and is of great value to future optimization and development of a drug of same.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
43.
CRYSTAL FORM OF UPADACITINIB, PREPARATION METHOD THEREFOR, AND USE THEREOF
A new crystal form of upadacitinib and a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a JAK1 inhibitor drug and drugs for treating rheumatic arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis, and psoriatic arthritis. Compared with the prior art, the crystal form of upadacitinib has one or more improved characteristics and is of great value for the optimization and development of drugs in the future.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
44.
CRYSTAL FORM OF UPADACITINIB AND PREPARATION METHOD AND USE THEREOF
The present disclosure relates to a crystalline form of upadacitinib and processes for preparation thereof. The present disclosure also relates to a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing a JAK inhibitor drug, and use of the crystalline form for preparing drugs treating rheumatoid arthritis. The crystalline form of upadacitinib provided by the present disclosure has one or more improved properties compared with prior art and has significant values for future drug optimization and development.
The present disclosure relates to a crystalline form of upadacitinib and processes for preparation thereof. The present disclosure also relates to a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing a JAK inhibitor drug, and use of the crystalline form for preparing drugs treating rheumatoid arthritis. The crystalline form of upadacitinib provided by the present disclosure has one or more improved properties compared with prior art and has significant values for future drug optimization and development.
The present disclosure relates to a novel crystalline form of upadacitinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical compositions containing the crystalline form, use of the upadacitinib crystalline form for preparing JAK inhibitor drug, and use of the upadacitinib crystalline form for preparing drugs treating rheumatoid arthritis. The crystalline form of upadacitinib provided by the present disclosure has one or more improved properties compared with prior art and has significant values for future drug optimization and development.
The present disclosure relates to a novel crystalline form of upadacitinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical compositions containing the crystalline form, use of the upadacitinib crystalline form for preparing JAK inhibitor drug, and use of the upadacitinib crystalline form for preparing drugs treating rheumatoid arthritis. The crystalline form of upadacitinib provided by the present disclosure has one or more improved properties compared with prior art and has significant values for future drug optimization and development.
Disclosed in the present invention are a new crystal form of upadacitinib, a preparation method therefor, a pharmaceutical composition containing the crystal form, and use of the crystal form in preparation of JAK inhibitor drugs and drugs for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis, and psoriatic arthritis. Compared with the prior art, the crystal form of upadacitinib provided by the present invention has one or more improved features, and is of great value to the optimization and development of this drug in the future.
The present disclosure relates to novel crystalline forms of tafamidis (hereinafter referred to as compound I) and processes for preparation thereof. The present disclosure also relates to pharmaceutical composition containing the novel crystalline forms, use of the novel crystalline forms for preparing drugs treating disease caused by transthyretin-mediated amyloidosis. The crystalline forms of tafamidis of the present disclosure have one or more improved properties compared with crystalline forms of prior art and have significant value for future drug optimization and development.
A crystal form of tafamidis free acid (I) and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and use of the crystal form in the preparation of a medicament for treating diseases caused by transthyretin amyloidosis. The crystal form of tafamidis free acid has one or more improved properties with respect to the prior art, having significant value for the optimization and development of the medicament in the future.
The present disclosure relates to novel crystalline forms of ARN-509 (structure shown in formula I), processes for preparation of the novel crystalline forms, pharmaceutical composition of the novel crystalline forms, and uses of the novel crystalline forms for preparing drug products of androgen receptor antagonists and for treating prostate cancer. The crystalline forms of ARN-509 provided by the present disclosure have one or more improved properties compared with the prior art, and is of great value to the future optimization and development of drugs.
The present disclosure relates to novel crystalline forms of ARN-509 (structure shown in formula I), processes for preparation of the novel crystalline forms, pharmaceutical composition of the novel crystalline forms, and uses of the novel crystalline forms for preparing drug products of androgen receptor antagonists and for treating prostate cancer. The crystalline forms of ARN-509 provided by the present disclosure have one or more improved properties compared with the prior art, and is of great value to the future optimization and development of drugs.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
50.
CRYSTAL FORM OF PONESIMOD, PREPARATION METHOD THEREFOR AND USE THEREOF
A novel crystal form of Ponesimod, a preparation method therefor, a pharmaceutical composition comprising the crystal form, and use of the crystal form in the preparation of a selective S1P1 receptor agonist drug and a drug for treating multiple sclerosis. The crystal form of Ponesimod has improved properties compared with the prior art, and can be used for the optimization and development of the drug.
Disclosed are a crystal of a compound I hydrochloride and a preparation method therefor, a pharmaceutical composition containing the crystal, and the use of the crystal in the preparation of a TYK2 inhibitor drug and a drug for treating psoriasis, systemic lupus erythematosus, and Crohn's disease. The crystal of the compound I hydrochloride has one or more improved properties compared with the prior art, and is of great value to the future optimization and development of the drugs.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
52.
DEUCRAVACITINIB CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF
Disclosed are a crystal form of a compound (I) and a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a TYK2 inhibitor drug and a drug for treating psoriasis, systemic lupus erythematosus, and Crohn's disease. The crystal form of compound I has one or more improved properties compared with the prior art and is of great value to the future optimization and development of the drug.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
53.
NEW CRYSTAL FORM OF ACALABRUTINIB, PREPARATION METHOD THEREFOR AND USE THEREOF
The present invention relates to a novel crystal form of Acalabrutinib, a preparation method therefor, a pharmaceutical composition having the crystal form, and uses of the crystal form in preparing a Bruton's tyrosine kinase inhibitor and a pharmaceutical preparation for treating mantle cell lymphoma. The new crystal form provided in the present invention has obvious cost advantages, and has one or more improved properties over the prior art, and is of great value for the optimization and development of the drug in the future.
The present invention relates to a cocrystal of dihydrochloride of compound I and a preparation method therefor, a pharmaceutical composition containing the crystal form and a use of the crystal form in preparing cardiac myosin activator drugs and drugs for treating heart failure. The cocrystal of dihydrochloride of compound I provided by the present invention, compared with the prior art, has one or more modified properties, and has important value for optimization and development of the drug in the future.
C07D 213/75 - Radicaux amino ou imino, acylés par un acide carboxylique, par l'acide carbonique ou par leurs analogues du soufre ou de l'azote, p. ex. des carbamates
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque
55.
RESMETIROM CRYSTAL, PREPARATION METHOD FOR SAME, AND USES THEREOF
A novel crystal of Resmetirom (referred to as "compound I"), a preparation method therefor, a pharmaceutical composition comprising the crystal, and uses of the crystal in preparing a THR-β selective agonist medicament and a medicament for treating NASH and HeFH. The crystal of compound I is provided with one or more improved properties compared with the prior art and provides important value in future optimization and development of the medicaments.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/02 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 5/14 - Médicaments pour le traitement des troubles du système endocrinien des hormones thyroïdiennes, p. ex. T3, T4
56.
BMS-986165 CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF
A crystal form of a compound I and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in the preparation of a TYK2 inhibitor drug and a drug for treating psoriasis, systemic lupus erythematosus, and Crohn's disease. The crystallization of the compound I has one or more improved properties compared to the existing technology, and has an important value to the future optimization and development of the drug.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
57.
Crystalline form of EB-1020, processes for preparation and use thereof
The present disclosure relates to a crystalline form of compound I and processes for preparation thereof. The present disclosure also relates to a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing serotonin, norepinephrine and dopamine triple reuptake inhibitors drugs, and/or use of the crystalline form for preparing drugs treating nervous system disorders. The crystalline form of the present disclosure has one or more improved properties compared with prior art and has significant values for future drug optimization and development.
C07D 209/52 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle condensés avec un cycle autre qu'un cycle à six chaînons
58.
Crystalline forms of a fatty acid bile acid conjugate, preparation method thereof and use thereof
The present disclosure relates to novel crystalline forms of compound (I) and processes for preparation and use thereof. Crystalline forms CS3, CS2, CS5 and CS8 of compound (I) of the present disclosure have advantages in at least one aspect of solubility, stability, melting point, hygroscopicity, particle size, bioavailability, processability, purification effect, flowability, adhesiveness, stability in drug product, in vitro and in vivo dissolution, etc., which provides new and better choices for preparation of drug product containing compound (I) and has significant values for future drug development.
C07J 41/00 - Stéroïdes normaux contenant un ou plusieurs atomes d'azote n'appartenant pas à un hétérocycle
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
59.
Crystal form of Baricitinib and preparation method thereof
The present disclosure relates to crystalline forms of Baricitinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical composition containing these crystalline forms and use of these crystalline forms for preparing JAK inhibitor drugs and preparing drugs treating rheumatoid arthritis. The crystalline forms of the present disclosure have one or more improved properties compared with crystalline forms of the prior art and have significant values for future drug optimization and development.
Disclosed are a new crystal form of tafamidis (compound I) and a preparation method therefor, a pharmaceutical composition containing the crystal form, and use of the crystal form in the preparation of a drug for treating diseases caused by transthyretin amyloidosis. The crystalline form of tafamidis has one or more improved properties compared with the prior art, and is of great value to the optimization and development of the drug in the future.
Disclosed are a new crystal form of Aprocitentan (referred to as "Compound I"), a preparation method therefor, a pharmaceutical composition comprising the crystal form, and the use of the crystal form in the preparation of dual endothelin receptor antagonist drugs and drugs for the treatment of refractory hypertension. The crystal form of Aprocitentan provided has one or more improved properties, which is of great value to the optimization and development of the drug in the future.
Disclosed are a new crystal form of compound I and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and the use of the crystal form in the preparation of hypoxia-inducible factor-prolyl hydroxylase inhibitor drugs and drugs for treating conditions mediated by hypoxia-inducible factors. The crystal form of compound I has one or more improved properties compared with that in the prior art, and is of great value to the optimization and development of such drugs in the future.
Disclosed are a new crystal form of Resmetirom (referred to as "compound I") and a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a THR-β selective agonist drug and a drug for treating NASH and HeFH. The crystal form of compound I has one or more improved properties compared with the prior art and is of great value to the future optimization and development of the drug.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
64.
Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
A crystalline form of valbenazine ditosylate, processes for preparation thereof, a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing vesicular monoamine transporter 2 inhibitor drugs, and use of the crystalline form for preparing drugs treating tardive dyskinesia.
The present disclosure relates to novel crystalline forms of ARN-509 (structure shown in formula I), processes for preparation of the novel crystalline forms, pharmaceutical composition of the novel crystalline forms, and uses of the novel crystalline forms for preparing drug products of androgen receptor antagonists and for treating prostate cancer. The crystalline forms of ARN-509 provided by the present disclosure have one or more improved properties compared with the prior art, and is of great value to the future optimization and development of drugs.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
66.
Crystal form of acalabrutinib and preparation method and use thereof
The present disclosure relates to novel crystalline forms of acalabrutinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical compositions containing acalabrutinib, use of acalabrutinib for preparing Bruton's tyrosine kinase inhibitor drug, and use of acalabrutinib for preparing drugs treating mantle cell lymphoma. The crystalline forms of the present disclosure have one or more improved properties compared with prior art, and have significant value for future drug optimization and development.
Disclosed are a new Upadacitinib crystal form and a preparation method therefor, a pharmaceutical composition containing the crystal form, and use of the crystal form in preparation of JAK inhibitors and drugs for treating rheumatoid arthritis. Compared with the prior art, the new Upadacitinib crystal form has one or more improved characteristics, and is of great value for the optimization and development of drugs in future.
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
68.
FILGOTINIB MALEATE CRYSTAL FORM CSI, PREPARATION METHOD THEREFOR AND USE THEREOF
A new Filgotinib maleate crystal form, a preparation method therefor, a pharmaceutical composition containing said crystal form, and use of the crystal form in the preparation of a JAK selective inhibitor and pharmaceutical formulations for treating rheumatoid arthritis, Crohn's disease, etc. Said Filgotinib maleate crystal form has one or more improved properties compared with the crystal forms in the art.
Provided are a new crystal form of dapagliflozin and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and a use of the crystal form in preparation of a sodium-glucose cotransporter inhibitor and a pharmaceutical preparation for treating diabetes. Compared with the prior art, the provided dapagliflozin crystal form CSI has one or more improved properties, and is of great value to the optimization and development of this drug in the future.
A61K 31/351 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle non condensés avec un autre cycle
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
70.
CRYSTAL FORM OF UPADACITINIB AND PREPARATION METHOD AND USE THEREOF
The present invention relates to a new crystal form of upadacitinib, and a preparation method, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a JAK inhibitor and medicine for treating rheumatoid arthritis. The crystal form of the upadacitinib provided by the present invention has one or more improved properties than in the prior art, and is of great value to the optimization and development of medicine in the future.
The present disclosure relates to novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation and uses thereof. Crystalline form CS1, form CS2 and form CS8 of the present disclosure can be used for preparing drugs treating anemia, which providing new choices for preparing drugs of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid, and having very important value for drug development.
The present invention relates to a novel cabozantinib malate crystal form, a preparation method for the cabozantinib malate, a pharmaceutical composition comprising the novel cabozantinib malate crystal form, and use of the novel cabozantinib malate crystal form in the preparation of MET, VEGFR1/2/3, ROS1, RET, AXL, NTRK, and KIT inhibitors and pharmaceutical preparations for treating cancers such as thyroid cancer, lung cancer, kidney cancer and liver cancer. The cabozantinib malate crystal form provided by the present invention has one or more improved properties compared with the prior art, and the preparation method for the carboxtinib malate provided by the present invention has a lower cost and better quality of the obtained product compared with the prior art, having important value for future optimization and development of this drug.
The present invention relates to a new crystal form of ARN-509 (the structure as shown in formula (I)) and a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form for preparing androgen receptor antagonists and pharmaceutical preparations for treating prostate cancer. The new crystal form of ARN-509 provided by the present invention has one or more improved properties compared to the prior art, and is of great value to the future optimization and development of the drug.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
The present disclosure relates to novel crystalline forms of VX-787, processes for preparation thereof and use thereof. VX-787 is a viral-protein inhibitor drug. The present disclosure provides crystalline form CS1, crystalline form CS2, crystalline form CS3, and crystalline form CS4 of compound (I) hydrochloride. The present disclosure also provides crystalline form CS3 and crystalline form CS9 of compound (I).free form.
The present invention relates to a new crystal form of Acalabrutinib and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in preparing a Bruton's tyrosine kinase inhibitor and a pharmaceutical preparation for treating mantle cell lymphoma. Compared with the prior art, the crystal form of Acalabrutinib provided by the present invention has one or more improved properties, and the future optimization and development of the drug is of great value. (I)
Provided are a crystal form of AP26113 and a preparation method therefor, a pharmaceutical composition containing the crystal form, and use of the crystal form in preparation of a tyrosine kinase inhibitor and a pharmaceutical preparation for treating ALK positive non-small cell lung cancer. The crystal form has one or more improved properties compared to the prior art, and has an important value for optimization and development of the medicament in the future.
C07F 9/6558 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant au moins deux hétérocycles différents ou différemment substitués ni condensés entre eux ni condensés avec un carbocycle commun ou un système carbocyclique commun
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
The present invention relates to a novel crystal form of SB-939, a preparation method thereof, a pharmaceutical composition containing the crystal form, and a use of the crystal form for preparing a histone deacetylase inhibitor and drug preparations for treating acute myeloid leukemia and/or myelodysplasia syndromes and/or myelofibrosis diseases. The crystal form of SB-939 provided by the present invention has one or more improved properties compared to the prior art, and has value for the future optimization and development of drugs.
The present invention relates to crystal form R of galunisertib, a preparation method and use thereof, a pharmaceutical composition comprising the crystal form, and a use of the crystal form in preparing a pharmaceutical preparation for treating myelodysplastic syndrome. The crystal form R provided by the present invention has one or more improved properties than the prior art and is of great value for the optimization and development of the drug in the future. (I)
The present invention relates to a novel crystal form of acalabrutinib, a preparation method thereof, a pharmaceutical composition comprising the crystal form, and a use of the crystal form in preparing a Bruton's tyrosine kinase inhibitor or a pharmaceutical preparation for treating mantle cell lymphoma. The crystal form of acalabrutinib provided by the present invention has one or more improved properties compared to the prior art and is of great value for the optimization and development of the drug in the future.
A crystal form of Valbenazine di-p-toluenesulfonate, a preparation method therefor, a pharmaceutical composition comprising the crystal form, and a use of the crystal form in the preparation of a vesicular monoamine transporter 2 inhibitor and a pharmaceutical preparation for treating tardive dyskinesia.
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
81.
CRYSTAL FORM OF EB-1020, PREPARATION METHOD THEREFOR AND USES THEREOF
The present invention relates to a crystal form of a compound (I), a preparation method therefor, a pharmaceutical composition containing the crystal form, and uses of the crystal form in preparation of 5-hydroxytryptamine, norepinephrine and dopamine triple reuptake inhibitor and/or a pharmaceutic preparation for treating nervous system disorders. As compared with the prior art, the crystal form of the compound (I) provided by the present invention has one or more improved properties, and is of great value for the optimization and development of the drug in the future. (I)
C07D 209/52 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle condensés avec un cycle autre qu'un cycle à six chaînons
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
82.
CRYSTAL FORM OF GALUNISERTIB AND PREPARATION METHOD THEREFOR AND USE THEREOF
The present invention relates to a crystal form O of Galunisertib, a preparation method therefor and use thereof, a pharmaceutical composition comprising the crystal form, and a use of the crystal form in preparing a pharmaceutical preparation for treating myelodysplastic syndrome. The crystal form O provided by the present invention has one or more improved characteristics when compared with the existing technology, having great value in the future of the optimization and development of the drug.
The present invention relates to a new crystal form of Acalabrutinib and a preparation method therefor, a pharmaceutical composition containing the crystal form, and use of the crystal form in preparing a Bruton's tyrosine kinase inhibitor and a pharmaceutical preparation for treating Mantle Cell Lymphoma. Compared with the prior art, the crystal form of Acalabrutinib provided by the present invention has one or more improved features, and is of great value to the future optimization and development of this drug. (I)
The present invention relates to a new crystal form of compound I and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and a use of the crystal form in preparing an A3 adenosine receptor agonist and a pharmaceutical preparation for treating rheumatic arthritis, psoriasis, osteoarthritis, or glaucoma. The crystal form of compound I provided in the present invention has one or more improved properties compared with the prior art, and has a significant value for medicinal optimization and development.
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
Disclosed are a crystal form P of galunisertib and a preparation method therefor and the use thereof, a pharmaceutical composition containing the crystal form, and the use of the crystal form in preparing pharmaceutical preparations for treating myelodysplastic syndrome. The crystal form P has one or more improved properties compared to the prior art, and has an important value for the optimization and development of the medicament in the future.
The present invention relates to a crystal form of a compound (I) and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and the use of the crystal form in the preparation of a preparation comprising a progesterone receptor modulator and a drug for treating uterine fibroids and/or endometriosis. The crystal form of the compound (I) provided by the present invention has one or more improved properties than the prior art, and is of great value to the optimization and development of the drug in the future.
A61K 31/567 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en position 17 alpha, p. ex. mestranol, noréthandrolone
Crystal forms of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, CS1 and CS9, preparation methods thereof, and uses of the same in preparing a pharmaceutical preparation for treating and/or preventing anemia.
The present invention relates to a crystalline form of ozanimod hydrochloride and a preparation method therefor. The crystalline form of ozanimod hydrochloride provided by the present invention can be used to treat autoimmune diseases, particularly multiple sclerosis and ulcerative colitis. The crystalline form of ozanimod hydrochloride provided by the present invention has advantages in at least one aspect of solubility, melting point, stability, dissolubility, bioavailability, processing properties, and purification, provides new and better choices for preparation of ozanimod-containing pharmaceutical preparations and is of great significance for drug development.
The present invention relates to a crystalline form L, a crystalline form H, and a crystalline form N of galunisertib, a preparation method therefor, and a use thereof, a pharmaceutical composition containing the crystalline forms, and a use of the crystalline forms for preparing a pharmaceutical preparation for the treatment of myelodysplastic syndrome. The crystalline form L, the crystalline form H, and the crystalline form N provided by the present invention have one or more improved characteristics over those in the prior art and are of great value for future optimization and development of the drug.
A crystal form of a compound Lemborexant, a preparation method therefor, a pharmaceutical composition comprising the crystal form, and use of the crystal form in the preparation of an orexin receptor antagonist and of a pharmaceutical formulation for treating insomnia and irregular sleep-wake rhythm disorder. The crystal form of the compound Lemborexant provided by the present invention has one or more improved properties with respect to the prior art, having great value for the optimization and development of this medicament in the future.
The present invention relates to a novel crystal of Neratinib monomaleate, a preparation method therefor, a pharmaceutical composition having the crystal, and uses of the crystal in preparing a tyrosine kinase inhibitor and a pharmaceutical preparation for treating breast cancer. The novel crystal of Neratinib monomaleate provided in the present invention is provided with one or more improved characteristics compared with the prior art and provides important value in the future optimization and development of the medicament.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
The invention relates to a crystal form of a compound (I), a preparation method and use thereof, a pharmaceutical composition containing said crystal form, and the use of the crystal form in preparing the prostaglandin D2 receptor 2 antagonist and a drug preparation for treating asthma or allergic dermatitis or allergic rhinitis. The crystal form provided by the invention has a low hygroscopicity, good stability and high dissolution rate, and the formulation thereof may be exploitable and provide new options for developing a drug containing a compound (I) with significant applications.
The invention relates to a crystal form of a compound (I), a preparation method and use thereof, a pharmaceutical composition containing said crystal form, and the use of the crystal form in preparing the prostaglandin D2 receptor 2 antagonist and a drug preparation for treating asthma, allergic dermatitis or allergic rhinitis. Said crystal form has a low hygroscopicity, good stability and high dissolution rate, and the formulation thereof is exploitable and may provide new options for developing a drug containing a compound (I).
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
C07D 213/74 - Radicaux amino ou imino substitués par des radicaux hydrocarbonés ou par des radicaux hydrocarbonés substitués
94.
CRYSTAL FORM XV OF LESINURAD AND PREPARATION METHOD THEREFOR
The present invention relates to a new crystal form of lesinurad, a preparation method therefor, a pharmaceutical composition containing the crystal form, and use of the crystal form in the preparation of a uric acid transporter inhibitor and a pharmaceutical preparation for treating hyperuricemia. The new crystal form of lesinurad provided in the present invention has one or more improved properties with respect to those in the prior art, having great value in the optimization and development of this medicament in the future.
The present invention provides a new crystal form of baricitinib, a preparation method thereof, a pharmaceutical composition comprising the crystal form, and a use of the crystal form in preparing a JAK kinase inhibitor or a pharmaceutical preparation for treating rheumatoid arthritis. The new crystal form of baricitinib provided by the present invention has one or more improved properties over the prior art and has an important value to the optimization and development of the drug in the future.
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
96.
CRYSTAL FORM OF FATTY ACID BILE ACID CONJUGATE, METHOD FOR PREPARING SAME, AND APPLICATION
The present invention relates to a novel crystal form of a compound (I), a method for preparing same, and an application. Crystal form CS3, crystal form CS2, crystal form CS5, and crystal form CS8 of the compound (I) provided by the present invention have advantages in at least one of the aspects of solubility, stability, melting point, hygroscopicity, particle size, bioavailability, processability, purification, fluidity, adhesiveness, stability in a preparation, and in vitro dissolution, provide a new and better option for preparation of a pharmaceutical preparation containing the compound (I), and are of great significance for pharmaceutical development.
C07J 41/00 - Stéroïdes normaux contenant un ou plusieurs atomes d'azote n'appartenant pas à un hétérocycle
C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p. ex. cholane, cholestane, coprostane
C07C 229/26 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant plus d'un groupe amino lié au squelette carboné, p. ex. lysine
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
97.
NEW CRYSTAL FORM OF LENVATINIB METHANESULFONATE AND PREPARATION METHOD THEREOF
The present invention relates to a new crystal form of a Lenvatinib methanesulfonate salt and a preparation method thereof, a pharmaceutical composition containing the crystalline form, and the use of the crystalline form in the preparation of a tyrosinase inhibitor and a pharmaceutical preparation for treating thyroid cancer. The new methanesulfonate crystal form of the present invention has obvious cost advantages, and has one or more improved properties over the prior art, and is of great value for the optimization and development of the drug in the future.
Venetoclax crystal forms and a preparation method therefor, the structural formula thereof is represented by formula (I), and such crystal forms may be directly obtained from crystallization in a solvent.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
The present invention relates to crystalline forms of a salt of compound (I), a preparation method therefor, and a use. The new crystalline forms CS7, CS9, CS1 and CS3 have low hygroscopicity, good stability, high purity, less likelihood of degrading, high solubility and good mechanical stability. The present invention provides a new and better alternative for the preparation of a drug containing compound (I), and has considerable significance for drug development.
The present invention relates to a crystalline form of a salt of compound (I), a preparation method therefor, and a use. The new crystalline form CS2 has low hygroscopicity, good stability, high crystalline form purity and high solubility. The present invention provides a new and better alternative for the preparation of a drug containing compound (I), and has considerable significance for drug development.
brevets
